Labatec Pharma SA
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes (NCT03435094) | Labatec Pharma SA | 2018-02-25 |
Track Labatec Pharma SA automatically
Every clearance here is in the API, with alerts when new ones post.